Tensions over a proposed 67-mile transmission line have rocked Maryland's farming communities, as the nation’s largest grid ...

Q3 2025 Management View Maria Pope, President and CEO, stated that "we delivered another strong quarter in Q3, and we maintain our laser focus on execution, driving value and advancing our five ...

Rated at 350 kW, the inverter features six maximum power point trackers (MPPTs) supporting up to 30 module strings. It operates within an MPPT voltage range of 480 V to 1,500 V, with a maximum input ...

The unit pumps out a continuous 3,600W of power through its dedicated TT-30 RV port with surge capability reaching 7,200W ...

Arthrosi Therapeutics has raised $153 million to bankroll its bid to clout gout. The series E financing gives the biotech the financial firepower to deliver data from two phase 3 trials next year. San ...

AI’s power hunger is driving a U.S. electricity boom, forcing tech giants to seek stable, low-carbon energy sources beyond intermittent renewables. Nuclear power—both conventional and modular—is ...

Georgia Power, in partnership with Switched Source and ARPA-E, has installed the Phase-EQ device in Macon to increase power line capacity by up to 20%, reduce load and voltage imbalances, and enhance ...

Bar what it described as a “placebo wobble,” Moonlake Therapeutics AG turned in positive results from the phase III trials of sonelokimab in treating hidradenitis suppurativa (HS), only to see its ...

After Loudoun supervisors earlier this year changed local zoning laws to prohibit data centers from being built by-right anywhere in the county, the work is now turning to determine specific ...

The Qatar Investment Authority is partnering with Blue Owl Capital Inc. to finance and invest in data centers, marking the sovereign wealth fund’s latest bet on the booming artificial intelligence ...

AI's next bottleneck isn't chips but electricity, with data centers consuming 4% of U.S. power and climbing. Iren offers the best risk-reward with dual crypto-AI exposure and Nvidia partnership status ...

Ionis Pharmaceuticals is eyeing a new rare disease approval after its antisense oligonucleotide zilganersen successfully improved mobility in patients with the neurological condition Alexander disease ...